

## INFECTIOUS DISEASE

# Diet-induced obesity promotes infection by impairment of the innate antimicrobial defense function of dermal adipocyte progenitors

Ling-juan Zhang<sup>1,2\*</sup>, Christian F. Guerrero-Juarez<sup>3,4,5,6,7</sup>, Stella X. Chen<sup>2</sup>, Xiaowei Zhang<sup>1</sup>, Meimei Yin<sup>1</sup>, Fengwu Li<sup>2</sup>, Shuai Wu<sup>1</sup>, Joyce Chen<sup>2</sup>, Min Li<sup>8</sup>, Yingzi Liu<sup>6,7</sup>, Shang I. B. Jiang<sup>2</sup>, Tissa Hata<sup>2</sup>, Maksim V. Plikus<sup>3,4,5,7</sup>, Richard L. Gallo<sup>2\*</sup>

Copyright © 2021  
The Authors, some  
rights reserved;  
exclusive licensee  
American Association  
for the Advancement  
of Science. No claim  
to original U.S.  
Government Works

Infections are a major complication of obesity, but the mechanisms responsible for impaired defense against microbes are not well understood. Here, we found that adipocyte progenitors were lost from the dermis during diet-induced obesity (DIO) in humans and mice. The loss of adipogenic fibroblasts from mice resulted in less antimicrobial peptide production and greatly increased susceptibility to *Staphylococcus aureus* infection. The decrease in adipocyte progenitors in DIO mice was explained by expression of transforming growth factor- $\beta$  (TGF $\beta$ ) by mature adipocytes that then inhibited adipocyte progenitors and the production of cathelicidin in vitro. Administration of a TGF $\beta$  receptor inhibitor or a peroxisome proliferator-activated receptor- $\gamma$  agonist reversed this inhibition in both cultured adipocyte progenitors and in mice and subsequently restored the capacity of obese mice to defend against *S. aureus* skin infection. Together, these results explain how obesity promotes dysfunction of the antimicrobial function of reactive dermal adipogenesis and identifies potential therapeutic targets to manage skin infection associated with obesity.

## INTRODUCTION

The excessive expansion of white adipose tissue (WAT) that is associated with obesity affects more than 20% of the global population (1–3) and promotes several human diseases (1, 4). It has been suggested that obesity can promote cardiovascular disease, cancer, and delayed wound healing by driving systemic inflammation (1, 4–7). However, although these observations provide a rational explanation for disorders related to increased inflammation and obesity, it remains unclear why the incidence of infection, an adverse event typically associated with immunosuppression, is increased in the obese population. The increasing prevalence of systemic medical complications associated with obesity requires better understanding of the mechanisms by which the expansion of adipose tissue promotes disease.

A key mechanism to combat infection is by the production of antimicrobial peptides and proteins (AMPs) (8, 9). These gene-encoded antibiotics are expressed by many organs and cell types in humans and in other animal models (8). AMPs are found in high concentrations within classical innate immune cells such as neutrophils and mast cells, as well as in epithelial cells such as keratinocytes and colonic epithelia (9, 10). Recently, the activation of dermal fibroblasts (dFBs) to differentiate into adipocytes was observed to be an important source of AMPs (11–12). Skin infection induces a subset of dFBs to differentiate into adipocytes, thus expanding the local dermal WAT (dWAT).

This event of reactive adipogenesis results in the transient production of large amounts of AMPs and was found to be essential for optimal defense against deep skin infection by *Staphylococcus aureus* (11–13). Given its location as the deepest layer of skin, dWAT is the final defensive barrier to systemic spread of virulent pathogens.

In addition to defense against infection, dWAT also has several other important nonmetabolic functions (14–16). Changes in the dermal adipocyte and adipocyte progenitor (AP) populations have been described during hair cycling (17, 18), wound repair (15, 19–21), skin fibrosis (22), and thermogenesis (23). A better understanding of how obesity alters dermal fat function could provide insight into the increased incidence of infection in the obese population and other obesity-related skin complications such as defective wound healing and hair loss.

The reported increase in dermal adipocytes associated with obesity appears to be counterproductive to the beneficial activity of dWAT in fighting infections. To address this apparent inconsistency, we sought to determine whether obesity has a negative effect on AMP production during the differentiation of fibroblast precursors into adipocytes, and whether this may explain decreased innate immune defense against infection that is seen in diet-induced obesity (DIO). Using several independent methods, including single-cell RNA sequencing (RNA-seq) (scRNA-seq) analyses and dual-color adipocyte lineage tracing, we sought to obtain in-depth knowledge of how DIO affects dermal adipogenesis. Furthermore, as DIO promotes expansion of mature adipocytes, a coculture system that combined mature adipocytes and APs was established to determine the underlying mechanisms by which DIO may inhibit the antimicrobial function of the dermal progenitors.

## RESULTS

### DIO increases susceptibility of the skin to *S. aureus* and inhibits reactive adipogenesis

To determine how DIO influences the capacity of dermal adipocytes to defend the skin against infection, we fed mice with high-fat diet

<sup>1</sup>State Key Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China. <sup>2</sup>Department of Dermatology, University of California, San Diego, La Jolla, CA 92093, USA. <sup>3</sup>NSF-Simons Center for Multiscale Cell Fate Research, University of California, Irvine, Irvine, CA 92697, USA. <sup>4</sup>Center for Complex Biological Systems, University of California, Irvine, Irvine, CA 92697, USA. <sup>5</sup>Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA 92697, USA. <sup>6</sup>Department of Mathematics, University of California, Irvine, Irvine, CA 92697, USA. <sup>7</sup>Department of Developmental and Cell Biology, University of California, Irvine, Irvine, CA 92697, USA. <sup>8</sup>Institute of Dermatology, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Chinese Academy of Medical Science and Peking Union Medical College, Nanjing 210042, China.

\*Corresponding author. Email: lingjuan.zhang@xmu.edu.cn (L.-j.Z.); rgallo@ucsd.edu (R.L.G.)

(HFD) or standard diet (SD) for 6 months and then challenged them with *S. aureus* by intradermal injection. After intradermal challenge with *S. aureus*, mice on HFD had significantly ( $P < 0.01$ ) increased lesion size (Fig. 1, A and B) and significantly increased bacterial colony-forming units (CFUs) recovered from the site of infection (Fig. 1C and fig. S1A). A similar phenotype was observed in a separate study in which mice on HFD were paired with mice on a nutrient- and calorie-matched low-fat diet (LFD) as control (fig. S1, B and C). Flow cytometry analyses of cells isolated from the skin at the site of infection revealed that recruitment of  $CD11b^+Ly6G^+$  neutrophils upon infection was not notably altered in HFD versus SD (Fig. 1D). However, analysis of platelet-derived growth factor receptor A-positive (PDGFRA<sup>+</sup>) dFBs after infection revealed that the activation of adipogenic dFBs identified as  $THY1^+Sca1^+$  cells was prominently impaired in obese mice compared to lean controls (Fig. 1, E and F).


In addition, other features of early adipogenesis including proliferation of preadipocytes (pADs) as shown by costaining for preadipocyte factor 1 (PREP1) and the proliferation marker 5-bromo-20-deoxyuridine (BrdU; fig. S1D), markers of early adipocyte differentiation phospho-CCAAT enhancer binding protein beta (pC/EBP $\beta$ ) and collagen type IV (COLIV) (Fig. 1G), expression of AMP cathelicidin (*Camp*) and expression of pAD marker genes (*Pdgfra* and *Sca1*) (Fig. 1, H and I, and fig. S1, E and F) were lower in the dWAT layer of obese mice. Skin from mice on HFD also showed increased expression of the profibrotic marker *Spp1* after infection (Fig. 1I). Together, these results show that obesity in mice results in loss of the dermal pool of pADs and inhibited capacity to initiate reactive adipogenesis and express cathelicidin AMP.

### scRNA-seq reveals defective activation of dFBs in obese mice


To further define how obesity alters the dermal immune response, we performed 3'-end scRNA-seq on cells isolated from whole dorsal skin of SD and HFD mice challenged with *S. aureus* skin infection (Fig. 2A) (24). In line with our fluorescence-activated cell sorting (FACS) results, scRNA-seq analyses (Fig. 2B and fig. S2A) demonstrated that the recruitment of *Ptprc/Cd45*<sup>+</sup> *Cd11b*<sup>+</sup> *S100a8*<sup>+</sup> neutrophils after *S. aureus* infection was not impaired in HFD skin, whereas *Pdgfra*<sup>+</sup> dFB clusters were greatly depleted in HFD mouse skin compared to SD mouse skin after infection (Fig. 2B).

We next identified 10 subclusters within the *Pdgfra*<sup>+</sup> *Dcn*<sup>+</sup> dFB population based on marker gene expression (Fig. 2, C and D). The top eight major subclusters constituted 97% of all dFB cells and were defined as reticular/pAD (RET/pAD) dFBs (C1, ~38%, *Col1a1*<sup>+</sup> *Cd36*<sup>+</sup> *Icam1*<sup>+</sup> *Cebpb*<sup>+</sup> *Pparg*<sup>+</sup>), RET interstitial (RI) adipogenesis-regulatory (AREG) cells-I (C2, ~16%, *F3*<sup>+</sup> *GPX3*<sup>+</sup>) (25), dermal sheath (C3, ~12%, *Tagln*<sup>+</sup> *Mest*<sup>+</sup>), dermal papillae (C4, ~10%, *Corin*<sup>+</sup> *Prdm1*<sup>+</sup> *Bmp4*<sup>+</sup> *Lef1*<sup>+</sup>), RI-AREG-II (C5, ~9%, *F3*<sup>+</sup> *Clec11a*<sup>+</sup> *Gpx3*<sup>+</sup>) (25), RI progenitors (C6, ~5%, *Wnt2*<sup>+</sup> *Anxa3*<sup>+</sup> *Dpp4*<sup>+</sup>) (26), and papillary (PAP) dFB (C7 and C8, ~4%). In samples from SD mice, three RI clusters (C2, C5, and C6) became depleted after infection, whereas the RET/pAD C1 cluster was slightly enriched compared to mock control (Fig. 2, E and F). In contrast, almost all dFB clusters (fig. S2B), including the RET/pAD cluster (Fig. 2F), were depleted in HFD skin after *S. aureus* infection.

*S. aureus* infection induced the expression of a panel of proadipogenic genes, including AMP *Camp*, pAD markers *Pdgfra* and *Thy1*, adipocyte markers *Mest* and *Plin2*, and innate immune receptor *Il1r1* in the C1 RET/pAD dFB



**Fig. 1. Dermal reactive adipogenesis upon *S. aureus* infection is lost in DIO mice.** (A and B) SD or HFD mice were infected intradermally for 3 days with *S. aureus* (SA), and infected skin was collected for lesion size measurement ( $n = 10$  per group). (C) Measurement of bacterial CFU from the infected edge area of the skin from SD or HFD mice ( $n = 10$  per group). (D) FACS plots for neutrophils (gated as viable  $Ly6G^+CD11b^{hi}$  cells) in the skin of uninfected or *S. aureus*-infected mice fed with SD or HFD (representative of  $n = 3$  per group). (E) FACS plots for *Thy1* and *Sca1* expression on  $CD31^-CD45^-PDGFR\alpha^+$  dFBs (representative of  $n = 3$  per group). (F) Quantification of the percentage of  $THY1^{hi}Sca1^{hi}$  cells in  $PDGFR\alpha^+$  dFBs ( $n = 3$  per group). (G and H) Skin sections of *S. aureus*-infected SD or HFD skin were stained with pC/EBP $\beta$  (red) and COLIV (green) to measure adipocyte differentiation (G), or CAMP [red in (H)] as indicated. Nuclei were stained by 4',6-diamidino-2-phenylindole (DAPI; blue). Scale bars, 100  $\mu$ m. (I) qRT-PCR analysis of *Camp* and *Spp1* mRNA expression in control (Ctrl) or *S. aureus*-infected SD or HFD skin (ratio to *Tbp*) ( $n = 3$  to 5 per group). Scale bars, 100  $\mu$ m (G and H). All error bars indicate mean  $\pm$  SEM. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , and \*\*\*\* $P < 0.0001$  (one-way ANOVA).



**Fig. 2. scRNA-seq analysis reveals defective activation of dFB in *S. aureus*-infected skin in DIO mice.** (A) Schematic of scRNA-seq experiment. Single cells were isolated from dorsal skin of SD or HFD mice challenged with or without *S. aureus* (SA) skin infection. Isolation, processing, and capture of single cells by droplet-based device, 3'-end scRNA-seq, and downstream cc. QC, quality control. (B) Assembly of multiple distinct datasets (SD, *S. aureus*-infected; HFD, mock-infected; HFD, *S. aureus*-infected) into a reference dataset (SD, mock-infected) visualized with uniform manifold approximation and projection (UMAP) showing changes in fibroblast/fibroblast-like and immune cell composition in DIO mice challenged with *S. aureus* infection. Putative cell community identity is defined on the bottom. Neutrophil cluster is shown in yellow and highlighted by a red circle; dFB clusters are shown in blue and highlighted in blue circle. (C) Subclustering of *Pdgfra*<sup>+</sup>/*Dcn*<sup>+</sup> dFBs and fibroblast-like cells. Ten putative cell clusters were identified, and each cluster is coded with a distinct color. Putative cell cluster identity was defined by bona fide biomarker expression. Agglomerative clustering demonstrates hierarchical relationships between *Pdgfra*<sup>+</sup>/*Dcn*<sup>+</sup> fibroblast and fibroblast-like cells. (D) Heatmap showing enriched genes for each subcluster of *Pdgfra*<sup>+</sup>/*Dcn*<sup>+</sup> fibroblasts and fibroblast-like cells. (E) Anchored *Pdgfra*<sup>+</sup>/*Dcn*<sup>+</sup> fibroblasts and fibroblast-like cells split by condition and visualized in UMAP space. SD, mock-infected (*n* = ~890 viable cells); SD, *S. aureus*-infected (*n* = ~741 viable cells); HFD, mock-infected (*n* = ~448 viable cells); and HFD, *S. aureus*-infected (*n* = ~119 viable cells) cell clusters are color coded. Broken circles demarcate changes in *Pdgfra*<sup>+</sup>/*Dcn*<sup>+</sup> cells across conditions. (F) Proportion of C1 RET/pAD, normalized to library size after quality control, across conditions. (G) Heatmap showing expression of selected markers in C1 RET/pAD fibroblasts per condition. (H) Subclustering of RET/pAD fibroblasts. Six putative cell clusters were identified and color coded. Putative cell cluster identity was defined. Agglomerative clustering demonstrates hierarchical relationships between RET/pAD fibroblast subtypes. (I) Heatmap showing expression of enriched gene markers in sC1–sC6 FIB subtypes from the RET/pAD fibroblasts under SD-SA condition. SD, standard diet; HFD, high-fat diet; M, mock; FIB, fibroblasts; RET, reticular; pAD, preadipocyte; RI, reticular interstitial; AREG, adipogenesis-regulatory cells; DS, dermal sheath; DP, dermal papillae; RI-P, RI progenitor; PAP, papillary.

subcluster in SD mice but not in HFD mice (Fig. 2G). Instead, HFD RET/pAD dFBs gained higher expression of profibrotic genes including *Tgfb1*, *Mmp3*, *Mmp13*, and *Spp1* (Fig. 2G) after infection. To further characterize *Camp*-producing RET/pAD cells, the C1 RET/pAD subcluster was reclustered into six additional subclusters (sC1 to sC6) (Fig. 2H). *Camp* expression was detected only in subcluster sC4 (Fig. 2I), which was characterized by an adipogenic gene signature (fig. S2, C to E) and was enriched with other genes associated with reactive adipogenesis and innate immune function such as *Pdgfra*, *Thy1*, *Cd24a*, *Cebpa*, *Il1r1*, *Mest*, *Plin2*, *Dgat1/2*, *Il1r1*, *Cxcl1*, and *Cxcl2* (Fig. 2I). These results support the conclusion that HFD results in a loss of the subpopulation of dFB that have the capacity to become mature adipocytes and express AMP upon *S. aureus* challenge.

### Lineage tracing of dermal adipocytes during HFD feeding

We next sought to characterize how HFD alters the adipogenic function of dFBs. Histologic assessment of the back skin of mice fed with HFD for 6 months showed thinning of the dermis, expansion of dermal adipocytes, and loss of dermal cells compared to back skin of SD control mice (Fig. 3, A and B, and fig. S3, A and B), suggesting that HFD promotes hyperplastic growth of adipocytes from dFBs followed by hypertrophic expansion of these adipocytes. To characterize this further, we crossed adipocyte-specific, tamoxifen (TAM)-inducible *Adiponectin-Cre* estrogen receptor driver (*Adipoq-CreER*) mice with a dual-fluorescent reporter mouse (*mTmG*). Upon TAM induction, existing adipocytes become labeled with green fluorescence (membrane-targeted green fluorescent protein, mG), whereas new adipocytes formed after TAM withdrawal become red fluorescent [membrane-targeted Tomato (mT)] (Fig. 3C). This permitted us to distinguish between adipocyte hyperplasia and hypertrophy. When existing adipocytes were pulse labeled with TAM during the first week of HFD, >95% of adipocytes at 6 months of HFD were new (red; Fig. 3D). In contrast, only a small portion (<20%) of dWAT adipocytes were new at 6 months of HFD when TAM was given at 2 months of HFD, and almost all adipocytes were green when TAM was given after 4 months of HFD. These results indicate that HFD triggers an initial hyperplastic growth of adipocytes from their dermal progenitors, which may lead to depletion of dermal AD progenitor pool. However, after 2 to 4 months of HFD, adipocyte hypertrophy accounts for the majority of the expansion seen in dWAT, leading to domination of mature adipocytes in the dermis.

### Mature adipocytes lose their antimicrobial potential

We next evaluated how adipocytes change their capacity to express AMPs during their maturation in vitro. Primary mouse AP cells (purified on the basis of *Sca1*<sup>+</sup> from neonatal mouse dFBs) were cultured from subconfluent (s.c.; day -3) to postconfluent (p.c.; day 0) conditions and then differentiated into early (days 2 to 5) and fully mature adipocytes (days 6 to 12) as seen by the appearance of large intracellular lipid droplets (Fig. 3E). The s.c. cells exhibited a spindle cell morphology and expressed high amounts of *Acta2*, *Ctgf*, and *Inhba* (Fig. 3, E and F). The expression of these profibrotic genes was down-regulated when cells became p.c. (designated as day 0). p.c. cells exhibited some typical pAD characteristics, including the presence of small lipid droplets, rounded cell morphology, and elevated expression of *Dcn*, *Cebpb*, *Mest*, *Tlr2*, and *Col4a1* compared to s.c. cells (Fig. 3, E and F). Upon initiation of adipocyte differentiation by the addition of dexamethasone, 3-isobutyl-1-methylxanthine (IBMX), indomethacin, and insulin, the expression of *Col1a1* and

*Dcn* decreased and the expression of *Sca1*, *Tlr2*, *Il1r1*, and *Cd24a* transiently increased during the first-day postdifferentiation. This was then followed by induction of early adipocyte genes including *Camp* and *Mest* until day 3 (Fig. 3F). The expression of antimicrobial gene *Camp* decreased with the later increase in mature adipocyte markers, including *Adipoq*, *Fabp4*, and *Leptin* (Fig. 3F). In line with this transcriptional response, cathelicidin protein (CAMP) was secreted in the early phase of differentiation, whereas later, more mature adipocytes lost cathelicidin expression and secreted more fatty acid binding protein 4 (FABP4), an adipokine produced by mature adipocytes (Fig. 3G). Antimicrobial function correlated with cathelicidin expression as culture supernatant from early adipocytes inhibited the growth of *S. aureus*, whereas supernatant from mature adipocytes did not (Fig. 3, H and I). These data demonstrate that innate antimicrobial defense is optimal in early adipocytes but as adipocytes further mature, they then undergo a loss of this host defense function. These in vitro observations were consistent with the loss of antimicrobial defense function observed in obese mice whose dermis is dominated by mature adipocytes at the expense of pADs.


### Mature adipocytes inhibit the adipogenic potential of dFBs

To determine whether the accumulation of mature adipocytes might also feedback to inhibit the capacity of the pAD pool of dFBs to acquire antimicrobial function, we tested the effect of mature adipocytes on the function of the immature dFB/AP cells (Fig. 4A). Three days of coculture of dFB/AP cells with mature adipocytes led dFB/AP cells to develop a notable spindle cell morphology characterized by cell stratification (Fig. 4B, left panel). Furthermore, dFB/AP cells exposed to mature adipocytes lost their adipogenic potential (Fig. 4B, right two panels), production of cathelicidin (Fig. 4C), and capacity to inhibit the growth of *S. aureus* (Fig. 4D and fig. S4A). These observations suggest that signaling from mature adipocytes to dFBs inhibits the capacity of adipocyte precursors to produce antimicrobial activity.

To understand the mechanism of this inhibition, we performed reactome pathway analysis of the transcriptomes of dFB/AP cocultured with mature adipocytes, which revealed several pathways that were influenced by exposure to the soluble products of mature adipocytes (Fig. 4, E and F). Four of the top five up-regulated pathways were related to transforming growth factor- $\beta$  (TGF $\beta$ ): smooth muscle contraction, signaling by TGF $\beta$ , extracellular matrix organization, and elastic fiber formation. In contrast, the top pathways down-regulated in dFB/AP by mature adipocytes were those associated with early adipocyte development such as lipid biosynthesis [sterol regulatory element binding protein (SREBP) and cholesterol pathways] and innate immune responses (interferon and cytokine signaling). Because these features were similar to the response of dFB/AP when treated with TGF $\beta$ 2 (fig. S4B) (11) or the s.c. day-3 fibrotic dFB (as shown in Fig. 3, E and F), we next compared the transcriptomes of these dFB/AP cells cultured under the three conditions. Venn diagram analyses revealed similarities between the responses of dFBs to mature adipocytes and TGF $\beta$ 2 (Fig. 4, G and H). Specific transcripts induced such as *Acta2*, *Ctgf*, and *Itga5* were downstream of TGF $\beta$ /profibrotic pathways, whereas down-regulated transcripts were associated with adipogenesis and innate immunity, for example, *Sca1*, *Dcn*, *Camp*, and *Tlr2* (Fig. 4, I and J, and fig. S4C). Together, these results suggested that TGF $\beta$  could drive the loss of adipogenic and antimicrobial activity associated with obesity.

### Fig. 3. Hypertrophic expansion of adipocytes promotes loss of their antimicrobial potential.


(A and B) Representative images for hematoxylin and eosin (A) or perilipin staining [green; (B)] of skin sections from mice at SD or HFD ( $n = 3$  to 6 per group). Blue bracket indicates the dermis, and red bracket indicates the dermal fat layer. Scale bars, 100  $\mu\text{m}$ . (C) Experimental scheme for analysis of adipocyte hyperplasia or hypertrophy during HFD feeding using the *Adipoq-CreER;mTmG* dual-fluorescence mouse model. (D) Representative images ( $n = 3$  per group) of skin sections from *Adipoq-CreER;mTmG* mice at 6 months after HFD feeding after adipocytes were pulse labeled by TAM for 1 week at indicated time during HFD feeding. Scale bars, 100  $\mu\text{m}$ . (E) Magnetic cell sorter–purified *Sca1*<sup>+</sup> primary neonatal dermal FB culture subjected to adipocyte differentiation. Phase contrast images showing cell morphology changes and lipid droplet formation through the differentiation time course. s.c., subconfluent; p.c., postconfluent. (F) qRT-PCR analyses showing the mRNA expression kinetics of listed fibrosis markers (*Acta2*, *Ctgf*, and *Inhba*), extracellular matrix (*Col1a1* and *Dcn*), innate immune receptors (*Tlr2* and *IL1r1*), pAD (*Sca1* and *CD24a*), and AD (*Cebpb*, *Pparg1*, *Pparg2*, *Camp*, *Mest*, *Col4a1*, *Adipoq*, *Fabp4*, and *Leptin*) as indicated.  $n = 3$  per group. (G to I) Conditioned medium collected from undifferentiated pAD or differentiating adipocytes at indicated days (d) were subjected to Western blotting for CAMP and FABP4 antibodies (G), and an in vitro antimicrobial assay against *S. aureus* (H). (I) Quantification of bacterial CFU shown in (H) ( $n = 3$  per group). All error bars indicate mean  $\pm$  SEM. \*\*\*\* $P < 0.0001$  (one-way ANOVA).



### Mature adipocytes inhibit innate immune function of dFBs through the TGF $\beta$ -TGFBR-SMAD2/3 pathway

To further investigate the role of TGF $\beta$  in the inhibition of the innate immune defense function of adipogenesis, we measured the production of TGF $\beta$ 1 and TGF $\beta$ 2 during adipocyte maturation. Mature adipocytes secreted significantly ( $P < 0.01$ ) more of these cytokines than immature pAD (Fig. 5A). We also observed that when dFBs were exposed to the products of mature adipocytes, there was rapid

nuclear translocation of SMAD2/3 and accumulation of phospho-SMAD2/3 (pSMAD2/3) in the nucleus of the immature dFBs (Fig. 5B). These findings were consistent with activation of the TGF $\beta$  receptor (TGFBR). To confirm whether TGF $\beta$  released from mature adipocytes was indeed responsible for this effect, dFB was pretreated with a TGFBR inhibitor (SB431542) before coculture with mature adipocytes. Inhibition of TGFBR effectively blocked the capacity of mature adipocytes to promote a fibrotic morphology in dFBs and partially



**Fig. 4. Adipocytes inhibit the adipogenic function of dFBs.** (A) Schematic for the in vitro coculture obesity model in which adipogenic dFB (pAD) seeded on a dish were cocultured with adipocytes (AD) seeded on a transwell insert on top. (B to D) dFBs seeded with or without AD coculture were subjected to adipocyte differentiation. (B) Representative phase contrast images ( $n = 3$  per group) showing AD coculture triggered fibrotic cell morphology in undifferentiated dFBs and inhibited the subsequent adipocyte formation during differentiation. Scale bar, 100  $\mu$ m. (C) *Camp* mRNA or CAMP protein expression in differentiating dFBs treated without or with AD coculture ( $n = 3$  per group). (D) In vitro antimicrobial assay against *S. aureus* ( $n = 3$  per group). (E and F) Reactome pathway analyses (E) or FPKM (fragments per kilobase of transcript per million mapped reads) correlation plots (F) of up- or down-regulated genes in dFB compared to controls upon AD coculture identified by bulk RNA-seq. IL, interleukin. (G and H) Venn diagram comparing up- or down-regulated genes in dFB with AD coculture, dFBs treated with TGF $\beta$ 2 and s.c. dFBs (day -3, 3 days before confluency). (I) Heatmap of the FPKM of indicated genes showing a similar up-regulation of TGF $\beta$ /profibrotic genes and down-regulation of proadipogenic and innate immune genes in dFBs treated with TGF $\beta$ 2 and dFBs seeded with AD coculture. (J) qRT-PCR validating the expression of select genes as indicated ( $n = 3$  per group). All error bars indicate mean  $\pm$  SEM. \**P* < 0.05, \*\**P* < 0.01, and \*\*\**P* < 0.001 (one-way ANOVA).

restored the adipogenic potential of these cells when exposed to differentiation conditions in the presence of mature adipocytes (Fig. 5C). Inhibition of TGFBR also restored expression of genes associated with reactive adipogenesis (*Sca1* and *Camp*) and blocked induction of profibrotic genes (*Ctgf* and *Acta2*) (Fig. 5D). The TGFBR inhibitor

also blocked the elevated protein expression of the profibrotic marker smooth muscle actin (SMA) on PDGFRA<sup>+</sup> dFBs that was promoted by mature adipocytes as shown by FACS analysis of SMA expression on gated PDGFRA<sup>+</sup> dFBs (Fig. 5, E and F, and fig. S5A).


In vivo, serum concentrations of TGF $\beta$ 2, but not TGF $\beta$ 1, were significantly ( $P < 0.01$ ) elevated in obese mice compared to lean mice (Fig. 5G and fig. S5B). TGF $\beta$ 2 protein was also detectable in perilipin<sup>+</sup> dermal mature adipocytes in dWAT of obese mice (Fig. 5H) and *Tgfb2* mRNA expression was significantly ( $P < 0.01$ ) elevated in the skin or epididymal WAT (EWAT) from obese HFD mice compared to lean SD controls (fig. S5C). Cultured primary fibroblasts isolated from the skin dermis or EWAT tissue of mice fed SD and HFD were gated by PDGFRA<sup>+</sup> and showed differential expression of SMA and *Sca1*. HFD promoted an increase in SMA<sup>hi</sup>*Sca1*<sup>lo</sup> cells and a decrease in the proadipogenic SMA<sup>lo</sup>*Sca1*<sup>hi</sup> cells both in the dermis and EWAT (Fig. 5, I and J). These SMA<sup>hi</sup>*Sca1*<sup>lo</sup> cells were profibrotic and had higher *Acta2* expression but low *Pref1* expression (fig. S5D), low adipogenic potential (fig. S5E), and expressed low amounts of *Camp* and *Adipoq* during differentiation (Fig. 5K). These findings of a pro-adipogenic to profibrotic shift in the dFB populations after HFD were consistent with the shift promoted by TGF $\beta$  during skin aging (11).

#### Rosiglitazone or inhibition of TGF $\beta$ signaling increases resistance of mice to *S. aureus* infection

Our observations suggested that mature adipocytes inhibit the antimicrobial function of dermal adipogenesis by producing TGF $\beta$ . To test this hypothesis, we used two independent methods to interfere or override TGF $\beta$  signaling in obese mice. The peroxisome proliferator-activated receptor- $\gamma$  (PPAR $\gamma$ ) agonist rosiglitazone was of interest as TGF $\beta$  suppresses the expression of PPAR $\gamma$ , a key transcription factor driving adipogenesis, and TGF $\beta$ -mediated suppression of PPAR $\gamma$  in fibroblasts has been

linked with skin and lung fibrosis (27, 28). In addition, the PPAR $\gamma$  agonist has been shown to attenuate TGF $\beta$ -mediated fibrogenesis in lung fibroblasts (28). Here, we found that rosiglitazone pretreatment protected dFBs from TGF $\beta$ 2-mediated suppression of adipogenic function in vitro (Fig. 6A and fig. S6A). Rosiglitazone also restored

**Fig. 5. Adipocytes inhibit the adipogenic function of dFBs through the TGF $\beta$ -TGFBR-SMAD2/3 pathway.** (A) Measurement of TGF $\beta$ 1 and TGF $\beta$ 2 concentrations in the culture supernatant collected from pAD or AD cells ( $n = 3$  per group). (B) SMAD2/3 (green) and pSMAD2/3 (red) immunostaining of dFBs seeded with or without AD coculture. Nuclei were stained by DAPI (blue). Scale bars, 50  $\mu$ m. (C to F) dFBs were cocultured with AD with or without SB431542 (SB; TGFBR inhibitor). (C) Phase-contrast images of undifferentiated or AD-differentiated cells. Scale bar, 100  $\mu$ m. (D) qRT-PCR of the indicated adipogenic genes (*Sca1* and *Camp*) or profibrotic genes (*Ctgf* and *Acta2*) ( $n = 3$  per group). (E) Representative FACS plots of SMA (AF488) and PDGFRA [allophycocyanin (APC)] ( $n = 3$  per group). The percentage of SMA<sup>hi</sup> PDGFRA<sup>+</sup> dFBs is highlighted in blue. (F) Quantification of the percentage of SMA<sup>hi</sup> cells in PDGFRA<sup>+</sup> dFB as shown in (E) ( $n = 3$  per group). n.s., nonsignificant. (G) Measurement of TGF $\beta$ 2 concentration in the serum of SD and HFD mice ( $n = 5$  per group). (H) Immunostaining of perilipin (green) and TGF $\beta$ 2 (red) in dermal fat of obese skin. Nuclei were stained by DAPI (blue). Scale bar, 100  $\mu$ m. (I) Representative FACS plots of SMA and Sca1 in cultured Pdgfra<sup>+</sup> dFBs isolated from skin or EWAT of SD or HFD mice as indicated ( $n = 3$  per group). Red, black, and blue numbers indicate the percentage of indicated cell fractions. (J) Bar charts showing the percentage of indicated FB population within cultured primary PDGFRA<sup>+</sup> FB from skin or EWAT. (K) Fibroblasts isolated from skin or EWAT of SD or HFD mice were treated with adipocyte differentiation medium, and mRNA expression of *Camp* or *Adipoq* in day 2 differentiated adipocytes (red bars) or undifferentiated cells (black bars) was measured by qRT-PCR as indicated ( $n = 3$  per group). All error bars indicate mean  $\pm$  SEM. \* $P < 0.05$ , \*\* $P < 0.01$ , and \*\*\* $P < 0.001$  (one-way ANOVA).




the adipogenic potential of cells exposed to TGF $\beta$ 2 as seen by increased capacity to secrete FABP4 (fig. S6B) and express *Pparg2*, *Adipoq*, *Camp*, and *Fabp4* (Fig. 6B and fig. S6C). Furthermore, combined rosiglitazone and TGFBR inhibitor SB431542 restored the adipogenic function of aged dFB (Fig. 6C), inhibited the expression of profibrotic genes (Fig. 6D), and induced proadipogenic genes (Fig. 6E). The combination of rosiglitazone and SB431542 worked the best to reverse the negative effects of coculture with mature adipocytes by decreasing expression of genes associated with fibrosis (*Acta2* and *Colla1*) while increasing genes associated with adipogenesis (*Pparg2*, *Adipoq*, and *Camp*) (Fig. 6, F and G, and fig. S6D). In vivo, administration of rosiglitazone and the TGFBR inhibitor also improved resistance to *S. aureus* infection in HFD obese mice, and the effect of both treatments combined was comparable to the improvement seen after treatment with either alone (Fig. 6H). Infected HFD mice treated with rosiglitazone and TGFBR inhibitor also had improved dermal reactive adipogenesis, including activa-

tion of C/EBP $\beta$  and increased cathelicidin AMP production in the dermal fat layer (Fig. 6, I and J).

To further test whether TGF $\beta$  drives the loss of host dermal defense against infection in obesity, we deleted expression of the TGFBR in dFBs. To achieve targeted deletion of *Tgfr2* specifically in *Pdgfra*<sup>+</sup> dFBs, *Tgfr2*<sup>flox/flox</sup> mice were bred with *Pdgfra*-Cre mice (Fig. 6K). As we have described in a previous study (11), no homozygous *Tgfr2*<sup>flox/flox</sup>; *Pdgfra*-Cre offspring were generated despite extensive breeding, and thus, experiments were conducted only with heterozygous *Tgfr2* deletion mice (*Tgfr2*<sup>flox/+</sup>; *Pdgfra*-Cre, *Tgfr2*<sup>Pd-/+</sup>) offspring and wild-type (WT) littermates (*Tgfr2*<sup>flox/flox</sup>). *Tgfr2*<sup>Pd-/+</sup> and WT littermates were fed with HFD for 6 months and then subjected to *S. aureus* intradermal infection. Heterozygous deletion of *Tgfr2* in dFBs significantly ( $P < 0.05$ ) increased the resistance of HFD mice compared to WT controls (Fig. 6L). The increased resistance to *S. aureus* in *Tgfr2*<sup>Pd-/+</sup> mice was not caused by an increased ability of blood neutrophils to kill *S. aureus* (Fig. 6M). These observations

**Fig. 6. Rosiglitazone protects dFBs from TGF $\beta$  and increases resistance of mice to SA infection.**

(A and B) Primary neonatal dFBs were pretreated with or without rosiglitazone (ROSI; 20  $\mu$ M), followed by treatment with or without TGF $\beta$ 2 (0.1 ng/ml) and then subjected to adipocyte differentiation. (A) Representative phase-contrast images showing adipocyte formation ( $n = 3$  per group). (B) qRT-PCR analyses of *Pparg2*, *Camp*, *Adipoq*, and *Fabp4* as indicated ( $n = 3$  per group). (C and D) Primary neonatal dFBs were treated with ROSI with or without SB431542 (SB; TGFBR inhibitor) and then subjected to adipocyte differentiation conditions. (C) Representative phase contrast images showing adipocyte formation ( $n = 3$  per group). (D and E) Heatmap showing relative mRNA expression (quantified by qRT-PCR) of selected fibrotic genes in undifferentiated cells and selected adipocyte genes in day 1 differentiated cells. (F and G) Neonatal dFB cocultured with AD with or without SB or ROSI as indicated. (F) Representative phase images showing adipocyte formation ( $n = 3$  per group). (G) qRT-PCR analyses of selected fibrotic genes or adipocyte genes ( $n = 3$  per group). (H to J) SD or HFD mice were treated with SB or ROSI then infected intradermally with *S. aureus*. (H) Measurement of bacterial CFU from the infection edge area of the skin ( $n = 5$  to 6 per group). (I and J) Skin sections were stained with pC/EBP $\beta$  (red) and COLIV (green) as shown in (I) or CAMP (red) and COLIV (green) as shown in (J). Nuclei were stained by DAPI (blue). Scale bars (A, C, F, I, and J), 100  $\mu$ m. (K) Conditional heterozygous *Tgfb2* deletion in *Pdgfra*<sup>+</sup> fibroblasts, *Tgfb2*<sup>fllox/+</sup>; *Pdgfra-cre* = *Tgfb2*<sup>Pd-/+</sup>, was achieved through the breeding of *Tgfb2*<sup>fllox/fox</sup> mice with *Pdgfra-cre* mice. (L to M) WT (*Tgfb2*<sup>fllox/fox</sup>) or *Tgfb2*<sup>Pd-/+</sup> mice were infected intradermally with *S. aureus*. (L) Effect of heterozygous deletion of *Tgfb2* in *Pdgfra*<sup>+</sup> dFBs on resistance of obese HFD mice to *S. aureus* intradermal infection as shown by measurement of bacterial CFU count in infected skin sites ( $n = 5$  to 8 per group). (M) *S. aureus* killing activity of whole mouse blood ( $n = 5$  per group). All error bars indicate mean  $\pm$  SEM. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , and \*\*\*\* $P < 0.0001$  (one-way ANOVA).



confirm the likely critical role of TGF $\beta$  signaling in suppressing innate antimicrobial defense against *S. aureus* infection seen in obese mice.


### Human skin from obese subjects also shows a loss of antimicrobial pADs

To determine whether observations in mice are also relevant to humans, we evaluated changes in adiposity and fibrotic features in the dermis of human skin samples collected from lean and obese Caucasian donors. Lipid (Bodipy) staining showed that whereas Bodipy<sup>+</sup> adipocytes were only detected in the lower dermis from lean subjects, Bodipy<sup>+</sup> cells were abundant through the upper dermis of the obese skin (Fig. 7A). Similar observations were also found in skin dermis collected from obese Asian skin donors (fig. S7A). Perilipin confirmed that adipocytes were present

in the dermis of obese subjects (fig. S7B). Quantitative reverse transcription polymerase chain reaction (qRT-PCR) analyses found that expression of *CAMP* and pAD marker *PREF1* was significantly ( $P < 0.01$ ) down-regulated in obese skin dermis compared to lean controls, whereas expression of *TGF $\beta$ 2* as well as profibrotic genes including *SPP1*, *FN1*, *COL3A1*, *COL1A1*, and *TIMP1* was elevated in obese dermis compared to lean controls (Fig. 7, B to E, and fig. S7, C to F). Together, these results in humans compare closely to our observations in obese mice.

### DISCUSSION

The recent observation that dermal adipogenesis is an important source of antimicrobial defense against infection (11, 12) appeared



**Fig. 7. Obesity promotes dermal adiposity, fibrosis, and loss of AMP expression in human skin.** (A) Representative Bodipy (green) and phalloidin (PHA) staining of human back skin sections from lean (BMI <23) and obese individuals (BMI >29). All individuals who participated in the study are white Caucasians ( $n = 3$  to 6 per group). Scale bar, 1 mm. (B to E) qRT-PCR analysis of indicated genes (ratio to housekeeping gene *HPRT*) in lean or obese human skin ( $n = 4$  to 5 per group). All error bars indicate mean  $\pm$  SEM. \*\* $P < 0.01$ ; n.s., nonspecific (unpaired Student's *t* test).

in conflict with many observations that obese individuals have an increased risk for bacterial skin infections (29–32). Here, we found that obesity impaired dWAT innate immune functions by at least three mechanisms. First, HFD feeding triggered hyperplastic growth of adipocytes from dermal progenitors, leading to depletion of dermal APs and accumulation of mature adipocytes. Second, mature adipocytes lost the capacity to produce AMP. Third, mature adipocytes also indirectly suppressed the adipogenic and antimicrobial potential of their progenitors by secreting TGF $\beta$ . Therefore, we have uncovered a pathological feature of obesity. This observation may also provide a critical link to explain associations between obesity and other systemic immune dysfunctions associated with AMP dysregulation (33–37).

Adipose tissue expansion results from an increase in adipocyte size (hypertrophy) or through differentiation of APs into mature, lipid-laden adipocytes, a process known as adipogenesis (hyperplasia)

(1, 2). We have shown that dermal fat expansion triggered by *S. aureus* infection involves both hyperplastic and hypertrophic modes (12) and termed this *S. aureus*-triggered adipocyte expansion as dermal reactive adipogenesis (13). During this event in immune defense, PDGFRA<sup>+</sup>THY1<sup>+</sup> APs proliferate locally and differentiate into new lipid-laden adipocytes that produce the AMP cathelicidin, conferring innate antimicrobial protection against bacteria (11, 12). It was not previously clear why excessive gain of fat during obesity would enable increased infection.

Adipose tissue expands by hypertrophy with or without hyperplasia in a depot-specific manner during HFD feeding of mice. It has been shown that DIO promotes the expansion of subcutaneous WAT primarily via hypertrophic growth of adipocytes, whereas it induces a transient proliferation of adipocyte precursors followed by adipocyte hypertrophy in perigonadal visceral WAT (2, 3). However, how dermal fat expands during DIO has not been elucidated. Here, using *Adipoq-CreER* lineage-tracing mice, we show that dermal fat expansion in response to HFD resulted from hyperplasia of adipocytes from dermal adipogenic fibroblasts. This was then followed by hypertrophic growth of mature adipocytes during the chronic phase of DIO. The adipogenic potential of dermal fat relies on the existence of a large pool of adipogenic progenitors residing in the RET layer of the dermis (38). These fibroblasts normally respond to *S. aureus* infection by locally differentiating into adipocytes and producing AMPs (11, 12). Our data now show that the dermal AP pool is depleted by DIO, leading to loss of defense protection from these APs.

To study the influence of adipocyte hypertrophy on antimicrobial function, we established an in vitro primary culture system in which Sca1<sup>+</sup> dermal APs were sequentially differentiated into pADs, early adipocytes, and then mature adipocytes. We found that upon commitment of APs to pADs and during early stages of adipocyte differentiation, pADs down-regulated the expression of genes associated with fibrosis but transiently up-regulated innate immune receptors including *Tlr2* and *Il1r* as well as the AMP *Camp*. These differentiating early adipocytes are an effective mechanism for immune defense as the conditioned medium from these early adipocytes potentially inhibited the growth of *S. aureus*. However, fully mature adipocytes lost this ability to limit bacterial growth. Therefore, pADs or early adipocytes are active in innate immune defense, but DIO leads to accumulation of mature adipocytes that do not fight against bacterial infection.

Activation of the TGF $\beta$  signaling pathway results in the loss of adipogenic precursors. TGF $\beta$  plays an important role in regulating many aspects of cellular processes such as proliferation, extracellular matrix production, and differentiation in adipose tissue (11, 26, 39, 40). Here, using a coculture model, we found that mature adipocytes not only lost the ability to suppress bacterial growth but also acted in a feedback loop to suppress the adipogenic and antimicrobial potential of their progenitors. The factors responsible for this negative feedback were TGF $\beta$ 1 and TGF $\beta$ 2. In vivo, obese mice showed increased serum concentrations of TGF $\beta$ 2, but not TGF $\beta$ 1. This observation suggests that adipocytes may be the major cellular source of TGF $\beta$ 2, whereas TGF $\beta$ 1 is also produced by immune cells such as regulatory T cells (41) and macrophages (42). A recent study has identified TGF $\beta$ 2 as an exercise-induced adipokine that regulates metabolism and attenuates adipose tissue inflammation in HFD-fed mice (39). In the current study, we found that TGF $\beta$ 2 treatment or adipocyte coculture not only suppressed the adipogenic potential of dFBs but

also led to innate immune suppression characterized by decreased expression of *Tlr2*, *Il1r1*, and inflammatory cytokines/chemokines. TGF $\beta$ 2-mediated immunosuppression may help to attenuate obesity-associated adipose tissue inflammation but is detrimental to the production of AMPs during reactive adipogenesis, which is necessary for optimal resistance to bacterial infection.

We showed the ability of rosiglitazone and a TGFBR inhibitor to restore normal antimicrobial functions in obese mice. However, multiple cell types participate in antimicrobial defense, and innate AMPs are secreted by other cells in the skin, such as keratinocytes, neutrophils, and mast cells (8, 9). Furthermore, other host defense processes including the action of reactive oxygen species, complement binding, and phagocytosis are essential for antimicrobial function. A limitation of our study is that only a mouse DIO model was used, and further studies are required to determine whether a similar defective reactive adipogenesis is present in humans and genetic models of obesity such as the db/db and ob/ob mice. Another limitation of this study is that observations of improved antimicrobial function in obese mice may also be due to influence on other cells, either directly by rosiglitazone or the TGFBR inhibitor or indirectly by effects on adipogenesis that enhance cell-mediated immune defense. The expression of cathelicidin has potent indirect activity on cell recruitment, cytokine release, and angiogenesis (33, 43, 44). Thus, although reactive adipogenesis and the production of AMPs by the differentiating pADs are important elements in host defense against *S. aureus*, it is likely that the direct antimicrobial function observed in vitro is not the only mechanism that explains the in vivo response.

Adipose tissue fibrosis is considered as a hallmark of adipose malfunction that is linked to insulin resistance (1, 45–47). Adipose fibrosis occurs when PDGFR $^+$  APs become activated and shift from adipogenesis to extracellular matrix–synthesizing profibrotic cells. However, how adipocyte hypertrophy triggers a shift in progenitor cell plasticity remains unclear. Here, we have shown that mature adipocytes secreted TGF $\beta$  ligands that promote a shift of dFBs from proadipogenic to profibrogenic. In DIO mice, dFBs failed to initiate a reactive adipogenesis program but, in turn, exhibited a profibrotic expression profile upon *S. aureus* skin infection. Whereas DIO promoted a notable profibrotic phenotype in mouse dermal fat upon infection, obesity-triggered dermal fibrosis was apparent in human skin even in the absence of infection. In human skin, increased dermal adiposity was associated with an increase in TGF $\beta$ 2 expression and a shift from adipogenesis to fibrosis characterized by a decrease in AMP gene expression and a gain of dermal fibrosis shown by thickened skin dermis and increased profibrotic gene expression.

Collectively, our data reveal how DIO impairs innate immune antimicrobial function and highlights a central role of TGF $\beta$  as an immunosuppressive adipokine. Our observations that infection by *S. aureus* in mice can be treated by inhibiting TGF $\beta$  or activating PPAR $\gamma$  may suggest a therapeutic approach to assist in resisting infections in the obese population.

## MATERIALS AND METHODS

### Study design

The main objective of this study is to determine whether DIO impairs the beneficial antimicrobial defense function of dermal fat against *S. aureus* and to determine the underlying mechanisms. A

DIO mouse model (60% HFD) was used to induce obesity in mice, and mice fed with standard or LFD were used as control. Intradermal infection with *S. aureus* was used as infection model as described previously (11, 12). In vivo phenotypes were characterized by analyzing neutrophil recruitment and dermal reactive adipogenesis on skin from HFD or SD mice infected with *S. aureus*. scRNA-seq was used to determine how HFD influences the skin immune response against *S. aureus* at a single-cell level. To determine how DIO affects dermal adipogenesis, a dual-color adipocyte-specific lineage-tracing mouse (AdipoqERT2Cre;mTmG) was used to characterize hyperplastic and hypertrophic growth of dermal adipocytes during HFD feeding. In vitro adipocyte differentiation from primary dermal pADs was established to determine how adipocytes change their antimicrobial function during maturation. In vitro coculture between mature adipocytes and undifferentiated pADs was used to determine whether the accumulation of mature adipocytes feedback to inhibit the adipogenic potential of pADs, and RNA-seq was performed to identify key upstream pathways driving the phenotype. TGF $\beta$  was identified as a key factor secreting by mature adipocytes to inhibit reactive adipogenesis. TGF $\beta$  is known to inhibit PPAR $\gamma$ , a key transcription factor for adipogenesis. Therefore, we used pharmacological inhibitor of TGFBR inhibitor and PPAR $\gamma$  agonist to determine whether the combination of these two treatments could restore reactive adipogenesis in the in vitro coculture model or in the obese mice in the in vivo infection model. Last, human skin samples were collected from lean and obese subjects to validate our key observations from mice in human clinical samples. All mice were randomly assigned to treatment groups, and all experiments were conducted with at least three technical replicates per group.

### Animals and animal care

All animal experiments were approved by the University of California, San Diego (UCSD) and the University of California, Irvine (UCI), Institutional Animal Care and Use Committee. C57BL/6 WT mice (Jackson Laboratory/JAX) were originally purchased from the Jackson laboratory and then bred and maintained in the animal facility at UCSD. C57BL/6 male mice were fed with 60% HFD (Research Diets Inc.) from 8 weeks of age for 6 months. In some studies, an LFD (LFD = 10% calories from fat; Research Diets Inc.) was used as nutrient- and calorie-matched control diet. *Adipoq-CreER* (JAX, 025124) and *mTmG* (JAX, 007576) mice were originally purchased from the Jackson laboratory and then bred, maintained, and fed with 60% HFD in the animal facility at the UCI. For all animal studies, animals were randomly selected without formal prandomization, and quantitative measurements were done without the opportunity for introduction of bias.

### Mouse model of *S. aureus* skin infection

Skin infection experiments were done as described (11, 12). *S. aureus* strain USA300/methicillin-resistant *S. aureus* was used for in vivo infection. In brief, the backs of sex- and age-matched adult WT were shaved, and hair was removed by chemical depilation (Nair). Mice were then injected intradermally with 100  $\mu$ l of a midlogarithmic growth phase of *S. aureus* ( $1 \times 10^7$  CFU of bacteria) in phosphate-buffered saline (PBS). Mice were sacrificed after day 3, and skin biopsies covering the infection edge or center area were harvested as described previously (11). Skin biopsies were homogenized in 1 ml of TRIzol (for RNA) or PBS (for CFU counting) with 2-mm zirconia beads in a Mini-Beadbeater 16 (Biospect). To count CFUs, homogenized

skin samples were serially diluted, plated onto Tryptic Soy Agar, and enumerated after overnight culture to quantify the CFU per site of infection. For some experiments, the PPAR $\gamma$  agonist rosiglitazone (10 mg/kg in PBS) or vehicle control was administered by daily intraperitoneal injection from 1 day before infection to day 2 of infection, and administration of TGFBR inhibitor SB431542 (0.125 mg in 100  $\mu$ l of 2% dimethyl sulfoxide + 30% polyethylene glycol 300 + PBS) or vehicle control was performed through intradermal injection within the infection site at 24 and 48 hours after infection. Skin biopsies were collected at day 3 after infection for RNA extraction or CFU counting as described above. For BrdU experiments, mice were injected intraperitoneally with BrdU (50 mg/g) 4 hours before being sacrificed for skin section collection.

### Human skin sample collection

Fresh adult human (Caucasian) full-thickness skin biopsies, from the back of lean [body mass index (BMI) <23] and obese (BMI >29) male donors between 50 and 65 years of age, were collected by the UCSD dermatology clinics. Fresh adult human (Chinese) full-thickness skin biopsies were collected by the Hospital for Skin Disease, Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College. All sample acquisitions were approved and regulated by the UCSD Institutional Review Board (reference number 140144) or by the Institute of Dermatology, Chinese Academy of Medical Science Medical Ethics Committee (reference number 2012003). Informed consent was obtained from all subjects before skin biopsies. All human biopsies were taken from the back skin, where it is relatively protected from sun exposure compared to other regions such as face and neck of the body. Upon collection, these samples were directly fixed with paraformaldehyde and then either paraffin embedded or optimum cutting temperature embedded for histological or immunofluorescent analyses.

### Statistical analysis

Experiments were repeated at least three times with similar results and were statistically analyzed by GraphPad Prism 8 software. For experiments with two groups, statistical significance was determined using Student's unpaired two-tailed *t* test. Normality was tested using the Shapiro-Wilk test, and for datasets that were not normally distributed, nonparametric tests were used to determine statistical significance. For experiments with more than two groups, one-way analysis of variance (ANOVA) multiple comparison test was performed as indicated in the legend. A *P* value of <0.05 was considered statistically significant (\**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001, and \*\*\*\**P* < 0.0001).

### SUPPLEMENTARY MATERIALS

stm.sciencemag.org/cgi/content/full/13/577/eabb5280/DC1

Fig. S1. Dermal reactive adipogenesis response upon *S. aureus* infection is lost in DIO.

Fig. S2. Identification of cell communities and cell cycle metrics on skin cells.

Fig. S3. DIO promotes expansion of dermal fat, thinning of skin dermis, and depletion of dermal cells.

Fig. S4. Adipocytes inhibit the adipogenic function of dFBs.

Fig. S5. Adipocytes inhibit the adipogenic function of dFBs through the TGF $\beta$ -TGFBR-SMAD2/3 pathway.

Fig. S6. Rosiglitazone protects dFBs from TGF $\beta$  in vitro.

Fig. S7. Obesity promotes dermal adiposity.

Table S1. Primers used for RT-qPCR of mouse genes.

Table S2. Primers used for RT-qPCR of human genes.

References (48–56)

[View/request a protocol for this paper from Bio-protocol.](#)

### REFERENCES AND NOTES

1. A. L. Ghaben, P. E. Scherer, Adipogenesis and metabolic health. *Nat. Rev. Mol. Cell Biol.* **20**, 242–258 (2019).
2. E. Jeffery, C. D. Church, B. Holtrup, L. Colman, M. S. Rodeheffer, Rapid depot-specific activation of adipocyte precursor cells at the onset of obesity. *Nat. Cell Biol.* **17**, 376–385 (2015).
3. Q. A. Wang, C. Tao, R. K. Gupta, P. E. Scherer, Tracking adipogenesis during white adipose tissue development, expansion and regeneration. *Nat. Med.* **19**, 1338–1344 (2013).
4. M. Grohmann, F. Wiede, G. T. Dodd, E. N. Gurzov, G. J. Ooi, T. Butt, A. A. Rasmiena, S. Kaur, T. Gulati, P. K. Goh, A. E. Treloar, S. Archer, W. A. Brown, M. Muller, M. J. Watt, O. Ohara, C. A. McLean, T. Tiganis, Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC. *Cell* **175**, 1289–1306.e20 (2018).
5. P. Zhao, K. I. Wong, X. Sun, S. M. Reilly, M. Uhm, Z. Liao, Y. Skorobogatko, A. R. Saltiel, TBLK1 at the crossroads of inflammation and energy homeostasis in adipose tissue. *Cell* **172**, 731–743.e12 (2018).
6. J. Ryu, C. A. Loza, H. Xu, M. Zhou, J. T. Hadley, J. Wu, H. You, H. Wang, J. Yang, J. Bai, F. Liu, C. Bialowas, L. Q. Dong, Potential roles of adiponectin isoforms in human obesity with delayed wound healing. *Cell* **8**, 1134 (2019).
7. C. L. Wu, K. A. Kimmerling, D. Little, F. Guilak, Serum and synovial fluid lipidomic profiles predict obesity-associated osteoarthritis, synovitis, and wound repair. *Sci. Rep.* **7**, 44315 (2017).
8. L.-J. Zhang, R. L. Gallo, Antimicrobial peptides. *Curr. Biol.* **26**, R14–R19 (2016).
9. R. L. Gallo, L. V. Hooper, Epithelial antimicrobial defence of the skin and intestine. *Nat. Rev. Immunol.* **12**, 503–516 (2012).
10. V. Nizet, T. Ohtake, X. Lauth, J. Trowbridge, J. Rudisill, R. A. Dorschner, V. Pestonjamas, J. Piraino, K. Huttner, R. L. Gallo, Innate antimicrobial peptide protects the skin from invasive bacterial infection. *Nature* **414**, 454–457 (2001).
11. L.-J. Zhang, S. X. Chen, C. F. Guerrero-Juarez, F. Li, Y. Tong, Y. Liang, M. Liggins, X. Chen, H. Chen, M. Li, T. Hata, Y. Zheng, M. V. Plikus, R. L. Gallo, Age-related loss of innate immune antimicrobial function of dermal fat is mediated by transforming growth factor beta. *Immunity* **50**, 121–136.e5 (2019).
12. L. J. Zhang, C. F. Guerrero-Juarez, T. Hata, S. P. Bapat, R. Ramos, M. V. Plikus, R. L. Gallo, Dermal adipocytes protect against invasive *Staphylococcus aureus* skin infection. *Science* **347**, 67–71 (2015).
13. S. X. Chen, L.-J. Zhang, R. L. Gallo, Dermal white adipose tissue: A newly recognized layer of skin innate defense. *J. Invest. Dermatol.* **139**, 1002–1009 (2019).
14. C. F. Guerrero-Juarez, M. V. Plikus, Emerging nonmetabolic functions of skin fat. *Nat. Rev. Endocrinol.* **14**, 163–173 (2018).
15. B. A. Schmidt, V. Horsley, Intradermal adipocytes mediate fibroblast recruitment during skin wound healing. *Development* **140**, 1517–1527 (2013).
16. R. K. Zwick, C. F. Guerrero-Juarez, V. Horsley, M. V. Plikus, Anatomical, physiological, and functional diversity of adipose tissue. *Cell Metab.* **27**, 68–83 (2018).
17. E. Festa, J. Fretz, R. Berry, B. Schmidt, M. Rodeheffer, M. Horowitz, V. Horsley, Adipocyte lineage cells contribute to the skin stem cell niche to drive hair cycling. *Cell* **146**, 761–771 (2011).
18. Z. Zhang, M. Shao, C. Hepler, Z. Zi, S. Zhao, Y. A. An, Y. Zhu, A. L. Ghaben, M.-Y. Wang, N. Li, T. Onodera, N. Joffin, C. Crewe, Q. Zhu, L. Vishvanath, A. Kumar, C. Xing, Q. A. Wang, L. Gautron, Y. Deng, R. Gordillo, I. Kruglikov, C. M. Kusminski, R. K. Gupta, P. E. Scherer, Dermal adipose tissue has high plasticity and undergoes reversible dedifferentiation in mice. *J. Clin. Invest.* **129**, 5327–5342 (2019).
19. C. F. Guerrero-Juarez, P. H. Dedhia, S. Jin, R. Ruiz-Vega, D. Ma, Y. Liu, K. Yamaga, O. Shestova, D. L. Gay, Z. Yang, K. Kessenbrock, Q. Nie, W. S. Pear, G. Cotsarelis, M. V. Plikus, Single-cell analysis reveals fibroblast heterogeneity and myeloid-derived adipocyte progenitors in murine skin wounds. *Nat. Commun.* **10**, 650 (2019).
20. M. V. Plikus, C. F. Guerrero-Juarez, M. Ito, Y. R. Li, P. H. Dedhia, Y. Zheng, M. Shao, D. L. Gay, R. Ramos, T.-C. Hsi, J. W. Oh, X. Wang, A. Ramirez, S. E. Konopelski, A. Elzein, A. Wang, R. J. Supapannachart, H.-L. Lee, C. H. Lim, A. Nace, A. Guo, E. Treffeisen, T. Andl, R. N. Ramirez, R. Murad, S. Offermanns, D. Metzger, P. Chambon, A. D. Widgerow, T.-L. Tuan, A. Mortazavi, R. K. Gupta, B. A. Hamilton, S. E. Millar, P. Seale, W. S. Pear, M. A. Lazar, G. Cotsarelis, Regeneration of fat cells from myofibroblasts during wound healing. *Science* **355**, 748–752 (2017).
21. B. A. Shook, R. R. Wasko, O. Mano, M. Rutenberg-Schoenberg, M. C. Rudolph, B. Zirak, G. C. Rivera-Gonzalez, F. López-Giraldez, S. Zarini, A. Rezza, D. A. Clark, M. Rendl, M. D. Rosenblum, M. B. Gerstein, V. Horsley, Dermal adipocyte lipolysis and myofibroblast conversion are required for efficient skin repair. *Cell Stem Cell* **26**, 880–895.e6 (2020).
22. R. G. Marangoni, B. D. Korman, J. Wei, T. A. Wood, L. V. Graham, M. L. Whitfield, P. E. Scherer, W. G. Tourtellotte, J. Varga, Myofibroblasts in murine cutaneous fibrosis originate from adiponectin-positive intradermal progenitors. *Arthritis Rheumatol.* **67**, 1062–1073 (2015).
23. I. Kasza, Y. Suh, D. Wollny, R. J. Clark, A. Roopra, R. J. Colman, O. A. MacDougald, T. A. Shedd, D. W. Nelson, M.-I. Yen, C.-L. E. Yen, C. M. Alexander, Syndecan-1 is required to maintain intradermal fat and prevent cold stress. *PLOS Genet.* **10**, e1004514 (2014).
24. E. Z. Macosko, A. Basu, R. Satija, J. Nemes, K. Shekhar, M. Goldman, I. Tirosh, A. R. Bialas, N. Kamitaki, E. M. Martersteck, J. J. Trombetta, D. A. Weitz, J. R. Sanes, A. K. Shalek,

- A. Regev, S. A. McCarroll, Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. *Cell* **161**, 1202–1214 (2015).
25. P. C. Schwalie, H. Dong, M. Zachara, J. Russell, D. Alpern, N. Akchiche, C. Caprara, W. Sun, K.-U. Schlaudraff, G. Soldati, C. Wolfrum, B. Deplancke, A stromal cell population that inhibits adipogenesis in mammalian fat depots. *Nature* **559**, 103–108 (2018).
  26. D. Merrick, A. Sakers, Z. Irgebay, C. Okada, C. Calvert, M. P. Morley, I. Percec, P. Seale, Identification of a mesenchymal progenitor cell hierarchy in adipose tissue. *Science* **364**, eaav2501 (2019).
  27. J. Wei, A. K. Ghosh, J. L. Sargent, K. Komura, M. Wu, Q. Q. Huang, M. Jain, M. L. Whitfield, C. Feghali-Bostwick, J. Varga, PPAR $\gamma$  downregulation by TGF $\beta$  in fibroblast and impaired expression and function in systemic sclerosis: A novel mechanism for progressive fibrogenesis. *PLOS ONE* **5**, e13778 (2010).
  28. E. El Agha, A. Moiseenko, V. Kheirollahi, S. De Langhe, S. Crnkovic, G. Kwapiszewska, M. Szibor, D. Kosanovic, F. Schwind, R. T. Schermuly, I. Henneke, B. A. MacKenzie, J. Quantius, S. Herold, A. Ntokou, K. Ahlbrecht, T. Braun, R. E. Morty, A. Günther, W. Seeger, S. Bellusci, Two-way conversion between lipogenic and myogenic fibroblastic phenotypes marks the progression and resolution of lung fibrosis. *Cell Stem Cell* **20**, 571–571 (2017).
  29. M. Karpelien, T. Siljander, J. Vuopio-Varkila, J. Kere, H. Huhtala, R. Vuento, T. Jussila, J. Syrjanen, Factors predisposing to acute and recurrent bacterial non-necrotizing cellulitis in hospitalized patients: A prospective case–control study. *Clin. Microbiol. Infect.* **16**, 729–734 (2010).
  30. S. Bartholomeeusen, J. Vandenbroucke, C. Truysers, F. Buntinx, Epidemiology and comorbidity of erysipelas in primary care. *Dermatology* **215**, 118–122 (2007).
  31. A. Dupuy, H. Benchikhi, J. C. Roujeau, P. Bernard, L. Vaillant, O. Chosidow, B. Sassolas, J. C. Guillaume, J. J. Grob, S. Bastuji-Garin, Risk factors for erysipelas of the leg (cellulitis): Case-control study. *BMJ* **318**, 1591–1594 (1999).
  32. R. Edmonds, J. Cuschieri, J. Minei, M. Rosengart, R. Maier, B. Harbrecht, T. Billiar, A. Peitzman, E. Moore, J. Sperry, Inflammation the Host Response to Injury Investigators, Body adipose content is independently associated with a higher risk of organ failure and nosocomial infection in the nonobese patient postinjury. *J. Trauma* **70**, 292–298 (2011).
  33. L.-J. Zhang, G. L. Sen, N. L. Ward, A. Johnston, K. Chun, Y. Chen, C. Adase, J. A. Sanford, N. Gao, M. Chensee, E. Sato, Y. Fritz, J. Baliwag, M. R. Williams, T. Hata, R. L. Gallo, Antimicrobial peptide LL37 and MAVS signaling drive interferon- $\beta$  production by epidermal keratinocytes during skin injury. *Immunity* **45**, 119–130 (2016).
  34. P. Y. Ong, T. Ohtake, C. Brandt, I. Strickland, M. Boguniewicz, T. Ganz, R. L. Gallo, D. Y. M. Leung, Endogenous antimicrobial peptides and skin infections in atopic dermatitis. *N. Engl. J. Med.* **347**, 1151–1160 (2002).
  35. R. Lande, J. Gregorio, V. Facchinetti, B. Chatterjee, Y.-H. Wang, B. Homey, W. Cao, Y.-H. Wang, B. Su, F. O. Nestle, T. Zal, I. Mellman, J.-M. Schröder, Y.-J. Liu, M. Gilliet, Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. *Nature* **449**, 564–569 (2007).
  36. P. M. Mihailovic, W. M. Lio, J. Yano, X. Zhao, J. Zhou, K.-Y. Chyu, P. K. Shah, B. Cercek, P. C. Dimayuga, The cathelicidin protein CRAMP is a potential atherosclerosis self-antigen in ApoE(-/-) mice. *PLOS ONE* **12**, e0187432 (2017).
  37. H. Benachour, M. Zaiou, A. Samara, B. Herbeth, M. Pfister, D. Lambert, G. Siest, S. Visvikis-Siest, Association of human cathelicidin (hCAP-18/LL-37) gene expression with cardiovascular disease risk factors. *Nutr. Metab. Cardiovasc. Dis.* **19**, 720–728 (2009).
  38. R. R. Driskell, B. M. Lichtenberger, E. Hoste, K. Kretschmar, B. D. Simons, M. Charalambous, S. R. Ferron, Y. Herault, G. Pavlovic, A. C. Ferguson-Smith, F. M. Watt, Distinct fibroblast lineages determine dermal architecture in skin development and repair. *Nature* **504**, 277–281 (2013).
  39. H. Takahashi, C. R. R. Alves, K. I. Stanford, R. J. W. Middelbeek, P. Nigro, R. E. Ryan, R. Xue, M. Sakaguchi, M. D. Lynes, K. So, J. D. Mul, M.-Y. Lee, E. Balan, H. Pan, J. M. Dreyfuss, M. F. Hirshman, M. Azhar, J. C. Hannukainen, P. Nuutila, K. K. Kalliokoski, S. Nielsen, B. K. Pedersen, C. R. Kahn, Y.-H. Tseng, L. J. Goodyear, TGF- $\beta$ 2 is an exercise-induced adipokine that regulates glucose and fatty acid metabolism. *Nat. Metab.* **1**, 291–303 (2019).
  40. P. Petrus, N. Mejhert, P. Corrales, S. Lecoutre, Q. Li, E. Maldonado, A. Kulyte, Y. Lopez, M. Campbell, J. R. Acosta, J. Laurencikienė, I. Douagi, H. Gao, C. Martinez-Alvarez, P. Heden, K. L. Spalding, A. Vidal-Puig, G. Medina-Gomez, P. Arner, M. Ryden, Transforming growth factor- $\beta$ 3 regulates adipocyte number in subcutaneous white adipose tissue. *Cell Rep.* **25**, 551–560.e5 (2018).
  41. R. Bommireddy, T. Doetschman, TGF $\beta$ 1 and T $\beta$ reg cells: Alliance for tolerance. *Trends Mol. Med.* **13**, 492–501 (2007).
  42. M. Keophiphath, V. Achard, C. Henegar, C. Rouault, K. Clement, D. Lacasa, Macrophage-secreted factors promote a profibrotic phenotype in human preadipocytes. *Mol. Endocrinol.* **23**, 11–24 (2009).
  43. C. A. Adase, A. W. Borkowski, L.-j. Zhang, M. R. Williams, E. Sato, J. A. Sanford, R. L. Gallo, Non-coding double-stranded RNA and antimicrobial peptide LL-37 induce growth factor expression from keratinocytes and endothelial cells. *J. Biol. Chem.* **291**, 11635–11646 (2016).
  44. K.-Y. Choi, N. Mookherjee, Multiple immunomodulatory functions of cathelicidin host defense peptides. *Front. Immunol.* **3**, 149 (2012).
  45. Y. Hasegawa, K. Ikeda, Y. Chen, D. L. Alba, D. Stiffler, K. Shinoda, T. Hosono, P. Maretich, Y. Yang, Y. Ishigaki, J. Chi, P. Cohen, S. K. Koliwad, S. Kajimura, Repression of adipose tissue fibrosis through a PRDM16-GTF2IRD1 complex improves systemic glucose homeostasis. *Cell Metab.* **27**, 180–194.e186 (2018).
  46. G. Marcelin, A. Ferreira, Y. Liu, M. Atlan, J. Aron-Wisniewsky, V. Pelloux, Y. Botbol, M. Ambrosini, M. Fradet, C. Rouault, C. Henegar, J. S. Hulot, C. Poitou, A. Torcivia, R. Nail-Barthelemy, J. C. Bichet, E. L. Gautier, K. Clement, A PDGFR $\alpha$ -mediated switch toward CD9<sup>high</sup> adipocyte progenitors controls obesity-induced adipose tissue fibrosis. *Cell Metab.* **25**, 673–685 (2017).
  47. T. Iwayama, C. Steele, L. Yao, M. G. Dozmorov, D. Karamichos, J. D. Wren, L. E. Olson, PDGFR $\alpha$  signaling drives adipose tissue fibrosis by targeting progenitor cell plasticity. *Genes Dev.* **29**, 1106–1119 (2015).
  48. R. Satija, J. A. Farrell, D. Gennert, A. F. Schier, A. Regev, Spatial reconstruction of single-cell gene expression data. *Nat. Biotechnol.* **33**, 495–502 (2015).
  49. J. Fan, N. Salathia, R. Liu, G. E. Kaeser, Y. C. Yung, J. L. Herman, F. Kaper, J.-B. Fan, K. Zhang, J. Chun, P. V. Kharchenko, Characterizing transcriptional heterogeneity through pathway and gene set overdispersion analysis. *Nat. Methods* **13**, 241–244 (2016).
  50. T. Stuart, A. Butler, P. Hoffman, C. Hafemeister, E. Papalexi, W. M. Mauck III, Y. Hao, M. Stoeckius, P. Smibert, R. Satija, Comprehensive integration of single-cell data. *Cell* **177**, 1888–1902.e21 (2019).
  51. L.-J. Zhang, Isolation, culture, and characterization of primary mouse epidermal keratinocytes. *Methods Mol. Biol.* **1940**, 205–215 (2019).
  52. F. Li, C. A. Adase, L.-J. Zhang, Isolation and culture of primary mouse keratinocytes from neonatal and adult mouse skin. *J. Vis. Exp.*, 56027 (2017).
  53. T. Hulsen, J. de Vlieg, W. Alkema, BioVenn—A web application for the comparison and visualization of biological lists using area-proportional Venn diagrams. *BMC Genomics* **9**, 488 (2008).
  54. G. Yu, L.-G. Wang, Y. Han, Q.-Y. He, clusterProfiler: An R package for comparing biological themes among gene clusters. *OMICS* **16**, 284–287 (2012).
  55. G. C. Rivera-Gonzalez, B. A. Shook, J. Andrae, B. Holtrup, K. Bollag, C. Betsholtz, M. S. Rodeheffer, V. Horsley, Skin adipocyte stem cell self-renewal is regulated by a PDGFA/AKT-signaling axis. *Cell Stem Cell* **19**, 738–751 (2016).
  56. J. J. Chia, T. Zhu, S. Chyou, D. C. Dasoveanu, C. Carballo, S. Tian, C. M. Magro, S. Rodeo, R. F. Spiera, N. H. Ruddle, T. E. McGraw, J. L. Browning, R. Lafyatis, J. K. Gordon, T. T. Lu, Dendritic cells maintain dermal adipose-derived stromal cells in skin fibrosis. *J. Clin. Invest.* **126**, 4331–4345 (2016).

**Acknowledgments:** We thank the UCSD flow cytometry core for FACS studies and the Xiamen University central biomedical instruments core for imaging studies. **Funding:** L.-j.Z. was supported by Chinese NSFC grants (81971551 and K2918001) and Xiamen University grant X2123303. R.L.G. was supported by NIH R01 AR076082, R37 AI052453, and U19 AI117673. M.V.P. was supported by a Pew Charitable Trust Grant, LEO Foundation Award, NIH grants R01-AR067273 and R01-AR069653, P30-AR075047, NSF grant DMS1763272, and Simons Foundation grant (594598 to Q. Nie). This work was also supported by U01-AR073159 (to Q. Nie, M.V.P., and X. Dai). C.F.G.-J. was supported by UC Irvine Chancellor's ADVANCE Postdoctoral Fellowship Program, NSF-Simons Postdoctoral Fellowship, NSF grant DMS1763272, Simons Foundation grant (594598 to Q.N.), and a gift from the Howard Hughes Medical Institute Hanna H. Gray Postdoctoral Fellowship Program. **Author contributions:** L.-j.Z. performed experiments, interpreted data, codirected the study, and wrote the manuscript. C.F.G.-J. performed scRNA-seq experiments and analyses and revised the manuscript. S.X.C., X.Z., and M.Y. performed experiments related to in vitro dFB-AD coculture. F.L. provided experimental assistance for primary culture and in vitro assays and in vivo mouse skin infection studies. S.W. performed bulk RNA-seq analysis for in vitro studies. J.C., S.J.B.J., and T.H. provided human healthy adult human biopsies from the UCSD dermatology clinics, and M.L. provided human skin biopsies from dermatology clinics in China. C.F.G.-J. and Y.L. generated mice and performed lineage-tracing experiments on adipocytes in mice. M.V.P. provided expertise related to scRNA-seq and adipocyte lineage tracing and revised the manuscript. R.L.G. conceived the studies, interpreted the data, directed the studies, and wrote the manuscript. **Competing interests:** R.L.G. is a cofounder, scientific advisor, and consultant; has equity in MatriSys Biosciences and is a consultant; receives income; and has equity in Sente. The other authors declare that they have no competing interests. **Data and materials availability:** All data associated with this study are present in the paper or the Supplementary Materials. scRNA-seq data are deposited at the NCBI GEO (<http://ncbi.nlm.nih.gov/geo/>) under accession GSE150729.

Submitted 2 March 2020

Resubmitted 29 May 2020

Accepted 7 December 2020

Published 20 January 2021

10.1126/scitranslmed.abb5280

**Citation:** L.-j. Zhang, C. F. Guerrero-Juarez, S. X. Chen, X. Zhang, M. Yin, F. Li, S. Wu, J. Chen, M. Li, Y. Liu, S. I. B. Jiang, T. Hata, M. V. Plikus, R. L. Gallo, Diet-induced obesity promotes infection by impairment of the innate antimicrobial defense function of dermal adipocyte progenitors. *Sci. Transl. Med.* **13**, eabb5280 (2021).

## Diet-induced obesity promotes infection by impairment of the innate antimicrobial defense function of dermal adipocyte progenitors

Ling-juan Zhang, Christian F. Guerrero-Juarez, Stella X. Chen, Xiaowei Zhang, Meimei Yin, Fengwu Li, Shuai Wu, Joyce Chen, Min Li, Yingzi Liu, Shang I. B. Jiang, Tissa Hata, Maksim V. Plikus and Richard L. Gallo

*Sci Transl Med* 13, eabb5280.  
DOI: 10.1126/scitranslmed.abb5280

### An obesity-infection connection

Obesity is known to increase the risk of skin infection. Zhang *et al.* show that increased numbers of mature adipocytes in a mouse model of diet-induced obesity led to increased TGF  $\beta$  signaling, which in turn reduced the abundance of dermal adipocyte progenitors. The remaining progenitors produced insufficient amounts of the antimicrobial peptide cathelicidin, thereby predisposing the obese mice to skin infection by *Staphylococcus aureus*. The PPAR  $\gamma$  agonist rosiglitazone or a TGF $\beta$  receptor inhibitor restored the ability of the obese mice to defend against infection. As dermal adipocyte progenitors were also reduced in obese individuals, targeting TGF  $\beta$  signalling may have clinical potential.

### ARTICLE TOOLS

<http://stm.sciencemag.org/content/13/577/eabb5280>

### SUPPLEMENTARY MATERIALS

<http://stm.sciencemag.org/content/suppl/2021/01/15/13.577.eabb5280.DC1>

### RELATED CONTENT

<http://stm.sciencemag.org/content/scitransmed/11/496/eaav1892.full>  
<http://stm.sciencemag.org/content/scitransmed/12/570/eaay5445.full>  
<http://stm.sciencemag.org/content/scitransmed/12/571/eaay7713.full>  
<http://stm.sciencemag.org/content/scitransmed/11/490/eaat8329.full>

### REFERENCES

This article cites 56 articles, 7 of which you can access for free  
<http://stm.sciencemag.org/content/13/577/eabb5280#BIBL>

### PERMISSIONS

<http://www.sciencemag.org/help/reprints-and-permissions>

Use of this article is subject to the [Terms of Service](#)

*Science Translational Medicine* (ISSN 1946-6242) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title *Science Translational Medicine* is a registered trademark of AAAS.

Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works